GLAXO.NS Live-Signale | Maximieren Sie Profite mit Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 12:00):

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally...

Stats
Tagesvolumen	228 005
Durchschnittsvolumen	166 204
Marktkapitalisierung	360.61B
EPS	INR0 ( 2024-02-11 )
Nächstes Ertragsdatum	( INR0 ) 2024-05-17
Last Dividend	INR32.00 ( 2023-06-30 )
Next Dividend	INR0 ( N/A )
P/E	68.03
ATR14	INR2.45 (0.11%)

Volumen Korrelation

Lang: -0.06 (neutral)

Kurz: -0.56 (weak negative)

Signal:(58.435) Neutral

GlaxoSmithKline Korrelation

10 Am meisten positiv korreliert
DALALSTCOM.NS	0.832

10 Am meisten negativ korreliert
LTGILTBEES.NS	-0.83
ANANDRATHI.NS	-0.821
KPIGLOBAL.NS	-0.807

Wussten Sie das?

Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).

Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.

GlaxoSmithKline Korrelation - Währung/Rohstoff

-0.11
( neutral )

0.05
( neutral )

-0.17
( neutral )

-0.23
( neutral )

0.44
( neutral )

0.43
( neutral )

GlaxoSmithKline Finanzdaten

Annual	2022
Umsatz:	INR32.52B
Bruttogewinn:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
Umsatz:	INR32.52B
Bruttogewinn:	INR19.67B (60.49 %)
EPS:	INR36.05

FY	2022
Umsatz:	INR32.78B
Bruttogewinn:	INR18.28B (55.78 %)
EPS:	INR22.48

FY	2021
Umsatz:	INR31.99B
Bruttogewinn:	INR18.04B (56.40 %)
EPS:	INR21.14

Financial Reports:

No articles found.

GlaxoSmithKline Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR60.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR32.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

GlaxoSmithKline Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.28 - low (42.21%) | Divividend Growth Potential Score: 5.02 - Stable (0.44%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.50	2003-04-10
Last Dividend	INR32.00	2023-06-30
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	INR435.25	--
Avg. Dividend % Per Year	1.67%	--
Score	2.77	--
Div. Sustainability Score	4.28
Div.Growth Potential Score	5.02
Div. Directional Score	4.65	--

Next Divdend (Est)
(2025-04-07)

INR32.69 Estimate 3.12 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.77

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR17.50	1.50%
2019	INR20.00	1.34%
2020	INR20.00	1.23%
2021	INR30.00	1.86%
2022	INR60.00	3.45%
2023	INR32.00	2.43%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
TOUCHWOOD.NS	Dividend Junior	2023-09-22	Annually	6	0.15%
PGIL.NS	Dividend Junior	2023-09-01	Annually	17	1.08%
JINDALSAW.NS	Dividend Junior	2023-06-13	Annually	22	1.62%
DEEPAKNTR.NS	Dividend Junior	2023-07-27	Annually	14	0.25%
SKMEGGPROD.NS	Dividend Junior	2023-08-30	Sporadic	21	0.95%
MGEL.NS	Dividend Junior	2023-08-08	Annually	5	0.59%
HARSHA.NS	Dividend Junior	2023-09-20	Insufficient data to determine frequency	2	0.09%
BDL.NS	Dividend Junior	2023-09-20	Semi-Annually	7	1.17%
PTC.NS	Dividend Knight	2023-09-20	Annually	21	6.06%
KDDL.NS	Dividend Junior	2023-09-22	Annually	8	0.29%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.160	1.500	6.81	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.322	1.500	7.53	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	519.54	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.24	2.00	6.88	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.604	1.000	3.27	3.27	[0.2 - 0.8]
operatingProfitMarginTTM	0.264	1.000	6.73	6.73	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.28

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	68.18	1.000	3.21	0	[1 - 100]
returnOnEquityTTM	0.322	2.50	8.41	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
dividendYielPercentageTTM	1.503	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.24	2.00	7.92	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.129	1.500	5.80	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0319	1.000	-1.702	0	[0.1 - 0.5]
Total Score				5.02

GlaxoSmithKline

GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.